News Sentiment

ABCL sentiment intelligence

Abcellera Biologics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 6.47 Week of 17 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-4.9% over one week, +16.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Negative

Abcellera Biologics, Inc. (8QQ) Q3 2025 Earnings Report - Results, Call & Slides

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -4.9% Price reacting lower
Trend fit Trend active 16.9% over four weeks
Fair value 62.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 33
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 19
Stock Titan 6
TradingView 5
simplywall.st 5
Moomoo 4
Simply Wall Street 3
Quartr 3
TipRanks 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 19
Analyst action 7
Deals and strategy 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 58
TipRanks Direct company coverage

Abcellera Biologics, Inc. (8QQ) Q3 2025 Earnings Report - Results, Call & Slides

Abcellera Biologics (8QQ) released its Q3 2025 earnings report, missing consensus EPS estimates by €0.04 with an actual EPS of -€0.17 versus an expected -€0.12. However, the company beat revenue expectations, reporting €7.85M against an expected €5.55M, representing a 37.62% year

Tone
Negative 42/100
Event
Earnings
Published
21 Jul 2026 23:09
Source
TipRanks
TipRanks Direct company coverage

Abcellera Biologics, Inc. (8QQ) Q3 2024 Earnings Report - Results, Call & Slides

Abcellera Biologics (8QQ) reported its Q3 2024 earnings, missing both EPS and revenue expectations. The company posted an actual EPS of -€0.15 against a consensus of -€0.11 and actual revenue of €5.70M compared to an expected €6.73M. The Q3 2024 earnings call was scheduled for No

Tone
Negative 30/100
Event
Earnings
Published
21 Jul 2026 22:41
Source
TipRanks
Simply Wall Street Direct company coverage

Does AbCellera’s New Board Appointment Reframe Its Execution Story for Investors in ABCL?

AbCellera Biologics announced the appointment of Lynn Seely, M.D., to its Board of Directors, bringing extensive experience in clinical development and commercialization, particularly in oncology. This appointment is expected to strengthen AbCellera's board-level expertise, align

Tone
Neutral 50/100
Event
Market update
Published
20 Jul 2026 06:10
Source
Simply Wall Street
Investing.com Direct company coverage

Cantor Fitzgerald reiterates Overweight on AbCellera stock at $11

Cantor Fitzgerald has reiterated an Overweight rating and an $11.00 price target for AbCellera Biologics (NASDAQ:ABCL). The firm anticipates positive Phase 2 data for AbCellera's anti-NK3R antibody ABCL635 in Q3 2026, expecting favorable comparisons to approved inhibitors and a s

Tone
Positive 72/100
Event
Analyst action
Published
18 Jul 2026 14:40
Source
Investing.com
Investing.com Nigeria Direct company coverage

Cantor Fitzgerald reiterates Overweight on AbCellera stock at $11 By Investing.com

Cantor Fitzgerald has reiterated an Overweight rating and an $11 price target on AbCellera Biologics (NASDAQ:ABCL). The firm anticipates positive Phase 2 data for AbCellera's anti-NK3R antibody ABCL635 in treating vasomotor symptoms in menopause, projecting significant upside for

Tone
Positive 71/100
Event
Analyst action
Published
18 Jul 2026 02:39
Source
Investing.com Nigeria
TradingView Direct company coverage

ABCL Stock Price and Chart — NASDAQ:ABCL

This article provides an overview of AbCellera Biologics Inc. (ABCL) stock, including its current price, market capitalization, key financial stats, and recent performance. It highlights the company's role as an AI-biotech firm specializing in therapeutic antibody discovery and i

Tone
Positive 70/100
Event
Market update
Published
14 Jul 2026 13:40
Source
TradingView
TradingView Direct company coverage

Weekly Recap: Lynn Seely board appointment and Benchmark upgrade to Buy

AbCellera Biologics (ABCL) has appointed Lynn Seely to its board as a Class III director, effective June 30, 2026. Concurrently, Benchmark upgraded the stock to Buy with an $11 target price. The company is set to report its Q2 2026 results on August 5, 2026, followed by an earnin

Tone
Positive 76/100
Event
Analyst action
Published
13 Jul 2026 11:40
Source
TradingView
Quiver Quantitative Direct company coverage

AbCellera Biologics Stock (ABCL) Opinions on Jazz Partnership and Analyst Upgrade

The article discusses positive sentiment surrounding AbCellera Biologics (ABCL) due to its partnership with Jazz Pharmaceuticals and a recent analyst upgrade. Key catalysts include upcoming Phase 2 data for ABCL635 and new executive hires. Insider buying activity and increased in

Tone
Positive 72/100
Event
Analyst action
Published
11 Jul 2026 14:09
Source
Quiver Quantitative
Quartr Direct company coverage

AbCellera Biologics (ABCL) TD Cowen 46th Annual Health Care Conference Summary

AbCellera Biologics (ABCL) presented at the TD Cowen 46th Annual Health Care Conference, highlighting its evolution from a technology platform to a biotech company with end-to-end capabilities, backed by over $1 billion in investment. The company detailed its strategic pipeline,

Tone
Positive 72/100
Event
Market update
Published
09 Jul 2026 11:12
Source
Quartr
Quartr Direct company coverage

AbCellera Biologics (ABCL) Q4 2024 earnings summary

AbCellera Biologics (ABCL) reported its Q4 2024 earnings, highlighting a strategic shift from a platform/partnership model to a clinical-stage biotech. The company is advancing two lead programs, ABCL635 and ABCL575, towards clinical trials in Q2 2025, and ended 2024 with over $8

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 00:09
Source
Quartr
Quartr Direct company coverage

AbCellera Biologics (ABCL) Stifel 2025 Healthcare Conference Summary

AbCellera Biologics (ABCL) has transitioned from a platform-focused partnership model to developing wholly owned clinical assets, with two assets now in the clinic and a third in IND-enabling studies. The company is primarily focused on its internal pipeline, including ABCL635 fo

Tone
Positive 66/100
Event
Deals and strategy
Published
08 Jul 2026 11:40
Source
Quartr
Moomoo Direct company coverage

Benchmark Upgrades AbCellera Biologics to Buy From Hold, Price Target Is $11

Benchmark has upgraded AbCellera Biologics (ABCL) from a Hold rating to a Buy rating, setting a new price target of $11. This revision indicates a positive outlook from the analyst firm regarding the company's future stock performance.

Tone
Positive 72/100
Event
Analyst action
Published
08 Jul 2026 11:40
Source
Moomoo
BioSpace Direct company coverage

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

AbCellera (Nasdaq: ABCL) announced that it will release its second quarter 2026 financial results on Wednesday, August 5, 2026. The company will also host an earnings conference call on the same day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live audio webcast and repl

Tone
Neutral 50/100
Event
Earnings
Published
08 Jul 2026 03:39
Source
BioSpace
Moomoo Direct company coverage

AbCellera Biologics Price Target Announced at $11.00/Share by Benchmark

Benchmark has set a price target of $11.00 per share for AbCellera Biologics (ABCL). This target suggests a potential upside for the stock from its current trading levels.

Tone
Positive 68/100
Event
Analyst action
Published
07 Jul 2026 23:39
Source
Moomoo
Moomoo Direct company coverage

Press Release: AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

AbCellera (Nasdaq: ABCL) announced it will release its second-quarter 2026 financial results on August 5, 2026. The company will host a conference call and webcast to discuss the results and provide a business update. A replay of the webcast will be available for 90 days.

Tone
Neutral 50/100
Event
Earnings
Published
07 Jul 2026 22:10
Source
Moomoo
Simply Wall Street Direct company coverage

What AbCellera Biologics (ABCL)'s New Oncology Veteran Director Means For Shareholders

AbCellera Biologics (ABCL) has appointed Dr. Lynn Seely, an oncology veteran, to its Board of Directors, bringing extensive experience in late-stage drug development and commercialization. While this strengthens the company's expertise in oncology, it doesn't immediately change t

Tone
Positive 63/100
Event
Market update
Published
07 Jul 2026 07:40
Source
Simply Wall Street
Stock Titan Direct company coverage

[Form 4] AbCellera Biologics Inc. Insider Trading Activity

AbCellera Biologics Inc. director Lynn Seely was granted 152,207 share options with an exercise price of $7.85 per share, expiring on July 1, 2036. These options will vest in three equal annual installments starting July 1, 2027, conditional on her continued service. The Form 4 f

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 22:40
Source
Stock Titan
Stock Titan Direct company coverage

AbCellera (ABCL) director Lynn Seely submits initial Form 3 insider ownership filing

AbCellera Biologics Inc. director Lynn Seely has filed an initial Form 3, which is a statement of beneficial ownership for insiders. The filing indicates no reported transactions or derivative positions, establishing her status as a reporting person. This form serves as an initia

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 22:40
Source
Stock Titan
Stock Titan Direct company coverage

Dr. Lynn Seely joins AbCellera (NASDAQ: ABCL) board as independent director

AbCellera Biologics Inc. (NASDAQ: ABCL) has appointed Dr. Lynn Seely as a new Class III independent director to its Board of Directors, effective June 30, 2026. Dr. Seely brings extensive biopharmaceutical executive experience, having previously served as president and CEO of Lye

Tone
Positive 72/100
Event
Market update
Published
06 Jul 2026 18:40
Source
Stock Titan
TradingView Direct company coverage

Lynn Seely appointed to AbCellera Board as Class III director

AbCellera has appointed Lynn Seely as a Class III director, effective June 30, 2026. She will serve until the 2029 annual meeting and has been deemed independent under NASDAQ and company guidelines. Seely will participate in the Non-Employee Director Compensation Policy but has n

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 18:40
Source
TradingView
Investing.com Direct company coverage

AbCellera appoints Lynn Seely to board of directors

AbCellera Biologics Inc. has appointed Lynn Seely, M.D., to its board of directors as an independent director. Seely brings extensive experience from her roles as CEO of Lyell Immunopharma Inc., former CEO of Myovant Sciences Inc., and CMO of Medivation Inc., where she oversaw th

Tone
Positive 66/100
Event
Market update
Published
06 Jul 2026 13:40
Source
Investing.com
Stock Titan Direct company coverage

If You Invested $1,000 in Abcellera Biologics Inc. (ABCL)

This article analyzes the historical performance of a $1,000 investment in Abcellera Biologics Inc. (ABCL) over various periods, showing significant volatility with a 101.2% return over one year but a -58.7% return over five years. It also provides a detailed overview of AbCeller

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 03:39
Source
Stock Titan
Stocktwits Direct company coverage

ABCL Stock Clocks Best Week Since February On Clinical Data Anticipation, Baker Bros Stake Boost

AbCellera Biologics (ABCL) shares experienced their best week since February, rising 18% due to anticipation of first-quarter 2026 earnings and crucial early-stage clinical data for its lead candidate, ABCL635. ABCL635 is designed as a non-hormonal treatment for menopause-related

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 10:12
Source
Stocktwits